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Abstract: 
T-lymphocytes are ideal targeting vehicles because (1) they are naturally equipped with 
trafficking capabilities, (2) they can undergo clonal expansion when they come in contact with antigen if 
given the appropriate mitogenic signals, (3) they release cytokines which recruit other 
inflammatoryhmmune cells, (4) they can initiate other arms of immunity at the tumor site and ( 5 )  they 
are capable of being engineered with powerful cytotoxins or enzymes. Both clonal expansion and 
recruitment of T-cells can greatly magnify targeted delivery, improving the therapeutic index of the 
intended diagnostic or treatment modality. Although lymphokine activated killer cells (LAK) and tumor 
infiltrating lymphocytes (TIL) have been tested in tumor targeting, the clonal frequency of tumor- 
specific lymphocytes is generally very low and <O.O 16% of administered lymphocytes arrive at the 
tumor sites, accounting for the limited efficacy and generalized toxicity of LAWTIL adoptive 
immunotherapy. Until the specific delivery of these cells is optimized, the potential of cell targeting 
cannot be explored. Quantitative analysis and trace-labeling of human lymphocytes for homing studies 
to human tumors in vivo have been limited by the unavailability of cell-labeling techniques and 
efficiency of gene transduction into T-cells. Issues unique to cellular targeting include homing 
properties of lymphocyte subpopulations (CD4+ vs CD8+ T-cells vs NK cells), clonal expansion of 
antigen-specific cells, and the cytotoxic potential of gene-modified T-cells. 
T-lymphocytes die of apoptosis when their TCR is engaged, unless costimulatory molecules on 
their cell surface are activated. To enhance the survival and proliferation of T lymphocytes reacting 
against tumor cells that lack costimulatory molecules, we previously reported the successful 
transduction of G~2-specific-scFv-CD28 chimeric immune receptor (CIR) into primary human 
peripheral blood CD8+ T-cells, which became selectively expanded when cultured with cells expressing 
both the MHC class I and G D ~ .  Thus, the transduced CIR carries out a functional costimulatory response 
that enhances their survival and selective expansion in the absence of natural costimulatory molecules. 
During the last funding period we have developed a novel affinity chromatography technique to rapidly 
clone efficient retroviral packaging cell lines. Using the pMSCVneo vector to carry the CIR and the 
packaging line GP+envAM 12, we can now transduce scFv-CD28-zeta-chain efficiently into primary 
human T-cells. The bulk culture achieves CIR monoclonality by 20 days of in vitro culture, achieving a 
40-fold expansion in cell number within 2 months. The transduced T-cells kill tumors in vitro in an 
antigen specific manner and suppressed tumor growth when injected iv into SCID mice bearing human 
tumor xenografts. We have achieved CIR gene transduction in two separate antigen systems, one for 
GD2 (5F11 scFv) and one for the antigen p58 (8H9scFv). The novel antigen p58 was chosen because of 
its broad and usually homogeneous distribution in human solid tumors, and most importantly, their 
absence on cell membranes of normal human tissues. In separate experiments, we have shown that T- 
cells transduced with the herpes simplex viral thymidine kinase (HSV-tk) gene can be radiolabeled with 
'311-FIAU to a safe nuclear radiation dose. Using a dicistronic construct we are inserting chimeric 
immune receptor plus HSV-tk into T-cells to allow such their trafficking to be radioactively monitored. 
We plan to study the role of cytokines, chemoreceptors and CD4 helper T-cells in recruiting CD8+ 
transduced T-cells to the tumor site. These studies should provide us with an adoptive cell therapy 
approach to target cytotoxicity to human tumors, and a lymphocyte tracking tool to study delivery to the 
tumor sites, to determine if they proliferate locally andor recirculate. Such pharmacologic information 
is crucial for optimizing gene-modified T-cells in future clinical trials. 
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1 .  Single chain v-Fragment (scFv) technology (Table 2)80 3G6, 3F8 and 5Fl l  are all anti-GD2 
murine monoclonal antibodies developed in our laboratory. 3G6 is a class switch variant of 3F8. 8H9 is 
a murine IgG1 antibody specific for the antigen gp58. The heavy and light chain cDNA of 3G6, 5F11, 
and 8H9 were joined by the linker (GGGGS)3 into scFv in a VH-VL orientation for 5F11 and 8H9, and 
VL-VH orientation for 3G6. Rat anti-idiotypic monoclonal antibodies were: A1 G4, idio2, C4E4, 
A2A6, C2H7 (for 3F8 and 3G6), 2E9 (for 8H9), and 1G9 (for 5F1 1).8' 
C2H7, A2A6 
GD2 1G8, I C 1  yes* Yes Yes 
~ 5 8  2E9.1E12. IF11 Yes yes 
Table 2: Parallel developments for anti-GD2 and anti-gp58 MoAb 
MoAb I Antiqen 1 Rat anti-idiotype I I S C F V - C D ~ ~  I ScFv-CD28- 
1 zeta chain 
3G6, I GD2 1 A lG4,  C4E4, idio2, 1 yes* I Yes 
2. Retroviral mediated gene transfer of chimeric immune receptor into primary human T-cells 
3G6-scFv-CD28 A CIR consisting of 3G6-scFv and the signal transduction domain of CD2858 
was constructed and high-titer producer cells were generated from the PG13 packaging cell line, with a 
titer of 7x1 O5 infectious particles per ml. PBMC were activated with phytohemagglutinin A and exposed 
to virus for 18 hours in the presence of polybrene (4 ug/ml). Three days after infection 28% to 40% of 
the CD3+ PBMC cells stained positively for the vector-encoded receptor in both CD4+ and CD8+ 
subsets. By FACS the transduced cells reacted with all 5 of 5 anti-idiotypic antibodies (i.e. Idio-2, 
C2H7, A2A6, C4E4, A1G4).8' By western blots, the scFv-CD28 chimeric protein (36 kDa in NIH 3T3 
fibroblasts and -40 kDa in Jurkat cells) was expressed as a dimer. The engagement of the 3G6-CD28 on 
Jurkat cells by the anti-idiotypic antibody A 1 G4 triggered the association 85 kDa regulatory subunit of 
PI3-kinase with the phosphorylated CD28. IL-2 secretion by transfectants stimulated with immobilized 
anti-CD3 MoAb required costimulation by either anti-CD28 MoAb 9.3, or AlG4, or short term culture 
with tumor cells expressing GD2. In contrast, in transfectants with the truncated 3G6-CD28 where 
CD28 signaling is disabled, or irrelevant transgene such as NTP (NGFR'", low affinity nerve growth 
factor receptor) AlG4 had no effect. The costimulatory effect of GD2-positive EL4 was completely 
abolished by the addition of GD2-specific F(ab')2. Thus, 3G6-CD28 specifically recognizes cell-surface 
GD2, leading to CD28-dependent signaling, including IL-2 secretion. 3G6-CD28-transduced T 
lymphocytes selectively survived CD3-dependent cell death in the presence of anti-idiotype A1 G4. In 
addition, A 1 G4 MoAb induced preferential expansion of 3G6-CD28-transduced primary T lymphocytes. 
Corecognition of MHC-peptide complexes and GD2 selectively activated PBMC expressing 3G6-CD28. 
CD8+ T cells transduced with 3G6-CD28 remained a constant fraction of all T cells (10*2%) when 
cocultured either with 3T3 cells alone, 3T3-A2.1, 3T3-A2.1/B7, or 3T3-GD2, but steadily increased to 
32&4% by day 12 if exposed to 3T3-A2.1/GD2. In control cultures, cells expressing 3G6-CD28TR or 
NTP remained unchanged. Thus, the increase in the fraction of 3G6-CD28-positive CD8+ T cells 
required both HLA A2.1 and GD2, which, on the other hand, had no effect on the transduced CD4+ 
subset. The same result was achieved in cultures of transduced CD8+ T cells in the absence of CD4+ 
cells. These data established that the engagement of 3G6CD28 with cell-surface GD2 antigen provides 
a powerful costimulatory signal to T cells specific for GD2-positive target cells. 
sc8H9-CD28-hTCR-C and scSFll-CD28-hTCR-C, The hCD8a leader-scFv-CD28 were ligated 
to hTCR-cchain to produce the gene hCD8-leader-8H9scFv-hCD28~~-hCD28,,~,-TCR< and hCD8- 
leader-5F 1 1 S C F V - ~ C D ~ ~ T M - ~ C D ~ ~ , , ~ , - T C R < .  These sequences were verified and ligated into the 
3 
pMSCVneo vector, and used to transfect the packaging line GP+envAM 12 bearing an amphotropic 
envelope and selected in G4 18. 
3. Use of anti-idiotype technology for rapid enrichment and cloning of producer lines by 
affinity column or cell sorting Anti-linker antibody may be useful in monitoring scFv gene expression. 
However, its efficiency depends on the accessibility of the scFv-linker portion. Although purified 
antigens can also be used to monitor scFv expression, certain classes (complex carbohydrates or 
unstable antigens) can be difficult to prepare and their chemistry highly variable. Without a 
standardized reagent for affinity purification or enrichment of virus producer cells, as well as monitoring 
and sorting of transduced lymphocytes, CIR technology remains inefficient. A dicistronic construct 
consisting of scFv-CD28-y and green fluorescent protein (GFP) exploited the latter to monitor gene 
transduction and to enrich producer lines.47 Although GFP can validate the gene transfer process, its 
added immunogenicity and its safety in clinical applications remain uncertain. Anti-idiotypic antibodies 
6 
o !  
4 
0.1 - 
0 30 60 90 1P 
looom 
loom 
iom 
im 
ID 
1 
0.1 1 I 
o BO 90 1 0  30 
0 30 60 90 120 
Number of days in culture 
are frequently used as antigen-mimics for infectious 
diseases and Internal image rat anti-idiotypic 
antibodies can be conveniently produced against mouse 
MoAb. Since large scale production of clinical grade 
MoAb is now routine, anti-idiotypic antibodies may be 
ideal surrogates especially if the antigen is not readily 
available. In addition, the biochemistry of 
immunoglobulins in positive selection (panning, affinity 
chromatography, sorting) and binding assays is well- 
known and is easy to standardize. Here we demonstrate 
that an anti-idiotypic MoAb against 8H9 can be used as a 
surrogate antigen for cloning CIR into primary human 
lymphocytes, i.e. a CIR of 8H9scFv, human CD28 and 
human TCR-I; chain. While previous studies showed that 
anti-idiotypic antibody can enhance cytotoxicity of scFv- 
yR-gene modified murine cytotoxic T-cell line,84 we now 
demonstrate that anti-idiotypic MoAb, besides allowing 
rapid affinity enrichment of producer cell line and 
monitoring of surface scFv expression, induces clonal 
expansion of CIR-modified primary human lymphocytes. 
Highly cytotoxic lymphocytes can be propagated in vitro 
undergoing lo6 fold expansion over a period of 6 months. 
The retroviral producer lines were affinity- 
enriched using MACS goat anti-rat IgG MicroBeads on the 
MiniMACS system (Miltenyi Biotec, Auburn, CA). 
Following each enrichment, viral supernatant from the 
producer line was used to infect the indicator cell line 
K562. Surface 8H9scFv expression on both the producer 
lines and the transfected K562 (4 days after infection) were 
measured by immunofluorescence using anti-idiotypic 
antibody 2E9. With each successive affinity enrichment 
(Figure 1A and IC) of producer line and subsequent 
successive subcloning (Figure 1B and lD), the surface 
expression (mean fluorescence) of 8H9-scFv increased and 
became more homogeneous for the producer clones 
(Figure 1A and 1B) as well as indicator line K562 (Figure 
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1 C and 1 D).Producer lines were stained with anti-idiotypic 
MoAb 2E9 before (shaded peak, A and B), and after first 
(dotted line peak, A) and second (thick solid line, A) 
affinity purification, and after first (dotted line, B) and 
second (solid line B) subcloning, showing improved scFv 
expression. Table 3 summarized the length of time (in 
weeks) required to clone high efficiency producer cell 
line. 
4. Long term propagation of CIR-transduced primary 
human lymphocytes. Following in vitro activation with 
anti-CD3 and anti-CD28, primary human PBMC were 
infected with the virus from producer line supernatant by 
centrifugation at 1000 xg for 60 minutes at room 
temperature. Using PBMC from normal volunteers, the in 
vitro requirement of IL2 and anti-idiotypic antibody for 
lymphocyte expansion was studied. On day 10 after gene 
transduction, 17-40% of cells became scFv-positive by 
FACS analysis. By day 15, 75-80% became positive and 
by day 24, 99% of the cells became positive. This clonal 
evolution to homogeneity was found in CD4+, CD8+ and 
the small CD56+ populations. IL-2 concentration of 50 to 
100 U/mL appeared optimum, and anti-idiotypic MoAb 
2E9 was absolutely necessary to maintain prolonged T- 
cell growth (Figure 2). Clonal expansion was expressed as 
fold expansion of initial viable lymphocyte number. IL-2 
(100 U/ml fig 2A, 50 U/ml fig 2B and 20 U/ml, fig 2C) 
was added after retroviral infection and was present 
throughout the entire in vitro culture period, in the 
presence (solid circles) or absence (open circles) of solid- 
phase anti-idiotypic antibody. Viable cell count was 
performed using trypan blue assay. These experiments 
were repeated twice with similar results. 
In the presence of 100 U/ml of IL2 and solid- 
phase anti-idiotypic antibodies, PBMC from 4 patients 
with stage 4 neuroblastoma off chemotherapy (Figure 
3B), two CTL sampless5 (Figure 3A) and 4 fresh blood 
specimens from two normal volunteers (Figure 3C), were 
expanded in vitro following CIR-gene transduction. 
Continual expansion (lo3 to lo8 fold) was achieved after 
150-200 days of culture, with a doubling time ranging 
from 5 to 10 days. 8H9scFv average gene copy number, 
transcript level, and surface expression were studied in 
these samples (Figure 4). The scFv-positive population 
enriched quickly during the first 20 days of culture in the 
absence of 2E9 (Figure 4A). As expected, the gene copy 
number and transcript level also plateaued with similar 
kinetics (Figure 4B). When the scFv-positive population 
became >95%, an average of 4.5 gene copies per cell 
5 
(range 2-9) was detected, which remained relatively stable throughout the extensive length of in vitro 
culture. ScFv expression was typically >95% throughout 6 months of culture (Figure 4A). The 
proportion of CD8+ cells versus CD4+ cells increased steadily to >50% by day 40 of culture, and 
decreased slowly over 3-4 months. At concentrations of IL-2 <50 U/mL, CD4+ cells outgrew the 
CD8+ population even faster (data not shown). 
4 
Transduced lymphocytes mediated non MHC-restricted antigen-specific cyto-toxicity in 
vitro against neuroblastoma and rhabdomyosarcoma cell lines In vitro cytotoxicity against NMB-7 
(Figure 5A) and LAN- 1 (Figure 5B) neuro-blastoma, or rhabdomyosarcoma HTB-82 (Figure 5C) were 
efficient. Antigen-dependence was demonstrated by the inhibition of cytotoxicities by MoAb 8H9. 
Table 3: Enrichment of Droducer Time %SCFV+ 
line 
No affinity purification 
No subcloning 
1 subcloning 
2 subclonings 
3 subclonings 
4 subclonings 
PGI 318HSscFv-CD28-MSCV 
With affinity purification 
PGI 318HSscFv-CD28-MSCV 
1 affinity purification 
2 affinity purifications 
3 affinity purifications 
4 affinity purifications 
+ 1 subcloning 
+ 2 subclonings 
GP+envAml2/8H9scF~-CD28-< 
1 affinity purification 
2 affinity purificatioi 
+ 1 subcloning 
+ 2 subclonings 
Cell sorting 
+ 1 subcloning 
1 affinity purification 
2 affinity purifications 
+ 1 subcloning 
+ 2 subclonings 
Cell sorting 
+ 1 subcloning 
(wks) 
0 
4 
8 
12 
16 
1 
2 
3 
4 
8 
12 
1 
2 
6 
10 
2 
6 
1 
2 
6 
10 
2 
6 
day 4 
7 
7 
15 
21 
25 
10 
18 
29 
33 
42 
54 
15 
30 
36 
57 
69 
74 
18 
25 
37 
50 
55 
63 
Daudi cell line (Figure 5D) was not killed 
because it was antigen-negative. This 
cytotoxicity was independent of target HLA 
expression or HLA types (data not shown). 
Unmodified lymphocytes from the same donor, 
cultured under the same conditions (100 U/ml 
of IL2), did not show antigen-specific killing 
(Figures 5) .  Control (5F 1 1 scFv) CIR modified 
lymphocytes also did not show antigen-specific 
killing of HTB82 (data not shown). In Elispot 
assays, IFN-)I secretion was detected when 
transduced lymphocytes were stimulated with 
antigen-positive tumors (NMB7 and HTB82) 
but not antigen-negative controls (Daudi, data 
not shown). Tumor cytotoxicity was 
demonstrated in CIR-gene modified T- 
lymphocytes whether they were derived from 
volunteers or from patients. This observation 
is important since T cells in patients and 
animals with growing tumors can have be 
defective in signal transduction.86 Whether 
these cells will consistently demonstrate anti- 
tumor effect in vivo, especially in the tumor 
environment, will require further studies. 
5. Targeting CIR-modified T cells to 
xenografts in SCID mice: developing an 
adoptive cell therapy model. 8H9scFv-CIR 
gene-modified lymphocytes suppressed HTB82 
tumor growth, when mixed at 1:l ratio at the 
time of tumor implantation (data not shown). 
The in vivo anti-tumor effect of 8H9scFv-CIR 
gene-modified lymphocytes was then tested in 
an established tumor model. Human 
rhabdomyosarcoma was strongly reactive with 8H9, but not with 5F11 (anti-GDz) antibodies. 5FllscFv- 
CIR gene-modified and IL-2 cultured lymphocytes were used as controls cells in adoptive therapy. 
5F 1 1 scFv-CIR contained the same CD28-TCRG construct used for 8H9scFv-CIR. Experiments were 
initiated when tumors grew to around 0.8 cm diameter. Control groups (Figure 6) were injected with 
either (1) no T cells but anti-idiotype 2E9 ip [A], (2) 5FllscFv-CIR modified lymphocytes 
6 
? intravenously plus anti-idiotype 1G8 (specific for 5F11 idiotype) ip [.I or (3) 8H9scFv-CIR modified 
lymphocytes i.v. plus A1 G4 (irrelevant anti-idiotypic antibody) ip [O]. Suppression of tumor growth 
was most significant with lymphocytes transduced with the 8H9scFv-CIR gene [O], p~0.05) ,  and only if 
the specific anti-idiotype 2E9 was administered. 5F 1 1 scFv-CIR modified lymphocytes or 8H9scFv- 
CIR plus A1G4 did not show significant anti-tumor effect when compared to control. This in vivo effect 
of gene-modified lymphocytes was demonstrated in 3 separate experiments. 
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